FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.
You may also be interested in...
FDA Should Consider Ethicist For Drug Safety Oversight Board, Science Board Chair Says
An ethicist could provide input on risk/benefit issues on behalf of the public, UT’s Shine suggests.
FDA Should Consider Ethicist For Drug Safety Oversight Board, Science Board Chair Says
An ethicist could provide input on risk/benefit issues on behalf of the public, UT’s Shine suggests.
FDA Drug Safety Board To Meet Every Six Weeks
The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.